Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab for Bladder Preservation in MIBC
NCT05445648Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Feb 2023
- Primary completion
- Feb 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in bladder cancer, sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT05445648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05445648.